Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.12
- Piotroski Score 2.00
- Grade Buy
- Symbol (HARP)
- Company Harpoon Therapeutics, Inc.
- Price $23.01
- Changes Percentage (0.09%)
- Change $0.02
- Day Low $22.99
- Day High $23.02
- Year High $23.21
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/08/2023
- Fiscal Year End N/A
- Average Stock Price Target $700.00
- High Stock Price Target $700.00
- Low Stock Price Target $700.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.53
- Trailing P/E Ratio -15.039215686275
- Forward P/E Ratio -15.039215686275
- P/E Growth -15.039215686275
- Net Income $-67,137,000
Income Statement
Quarterly
Annual
Latest News of HARP
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Ghiroli: Juan Soto's free agency has shades of Bryce Harper, Manny Machado
Juan Soto, a star player, missed out on a World Series win but is set to secure a massive contract in free agency. His potential deal could surpass records, with speculations of it reaching $500 milli...
By The New York Times | 4 days ago -
Japan's economic growth likely cooled sharply in Q3 in test for BOJ policy: Reuters poll
By Satoshi SugiyamaTOKYO (Reuters) - Japan's economy is expected to have slowed sharply in the third quarter hurt by sluggish consumption and capital spending, a Reuters poll showed, which could c...
By Reuters | 4 days ago -
Starbucks CEO promises return of Sharpie pens, condiment stations, free non-milk after disappointing Q4 earnings
Starbucks CEO Brian Niccol aims to revamp the company's strategy after disappointing Q4 results. Niccol's plan includes simplifying the menu, improving service speed, and reintroducing personal touche...
By Yahoo! Finance | 5 days ago
